Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from SynAct Pharma AB ( (SE:SYNACT) ) is now available.
SynAct Pharma AB announced that Hunter Capital AB has acquired 1,375,000 warrants and 500,000 shares from Heights Capital Management. This transaction is seen as a strategic move to enhance stability and predictability in SynAct’s shareholder base, as Hunter Capital has agreed not to convert the warrants into shares, allowing SynAct to focus on its strategic and developmental goals.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm, focusing on the resolution of inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, helping patients achieve immune balance.
YTD Price Performance: 112.16%
Average Trading Volume: 155,880
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.01B
Learn more about SYNACT stock on TipRanks’ Stock Analysis page.